CTOs on the Move

Alexion Pharmaceuticals

www.alxn.com

 
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.alxn.com
  • 100 College St
    New Haven, CT USA 06510
  • Phone: 203.272.2596

Executives

Name Title Contact Details

Similar Companies

Genizon BioSciences

Genizon BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BC International Corporation

BC International Corporation is a Dedham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marligen Biosciences

Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CollabRx

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world`s knowledge on genomics-based medicine with specific insights from the nation`s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.